CLAIMS

1. A pharmaceutical composition comprising a suspension comprising (i) from about 35% to 70% (w/w) drug particles, (ii) from 19% to 30% (w/w) of one or more water-immiscible compounds, (iii) from 2% to 16% (w/w) water, and (iv) from 1% to 8% (w/w) surfactant, wherein the pharmaceutical composition is physically stable.

2. A pharmaceutical composition comprising a suspension comprising (i) from about 20% to about 80% (w/w) solid excipients; (ii) from about 5% to 60% (w/w) drug particles, (iii) from 19% to 30% (w/w) of one or more water-immiscible compounds, (iv) from 2% to 25% (w/w) water, and (v) from 1% to 10% (w/w) surfactant, wherein the pharmaceutical composition is physically stable.

3. A pharmaceutical composition comprising a suspension comprising (i) an oil, and (ii) from about 35% to 70% (w/w) solid drug particles comprising levodopa or a levodopa prodrug and/or carbidopa or a carbidopa prodrug, wherein the pharmaceutical composition has a dynamic viscosity of at least 100 cP at 37 °C.

4. The pharmaceutical composition of claim 3, wherein said suspension comprises less than or equal to about 30% (w/w) of said oil.

5. The pharmaceutical composition of claim 4, wherein said suspension comprises greater than or equal to about 19% (w/w) of said oil.

6. The pharmaceutical composition of claim 4, wherein said suspension comprises water and a surfactant.

7. The pharmaceutical composition of claim 1, wherein said suspension has a dynamic viscosity of at least 100 cP at 37 °C.

8. The pharmaceutical composition of claim 7, wherein the D_{50} of the drug particles is greater than or equal to 1 µm and less than or equal to 500 µm.

9. The pharmaceutical composition of claim 8, wherein said suspension does not cream or sediment when centrifuged for 1 hour at an acceleration of about 5,000 G at 25 ± 3 °C.

10. The pharmaceutical composition of claim 9, wherein after said centrifugation for 1 hour at an acceleration of about 5,000 G at 25 ± 3°C the concentrations of drug in the layer containing the top 20 volume % and the layer containing the bottom 20 volume % of the composition differ by less than 6%.

11. The pharmaceutical composition of claim 8, wherein the shelf life of said pharmaceutical composition is 6 months or longer at 5 ± 3 °C and said pharmaceutical composition does not substantially cream or sediment when stored for 6 months at 5 ± 3 °C.

12. The pharmaceutical composition of claim 9, wherein said suspension comprises less than or equal to about 12% (w/w) water.

13. The pharmaceutical composition of claim 12, wherein said suspension comprises 8 ± 2% (w/w) water.

14. The pharmaceutical composition of claim 7, comprising an edible oil.

15. The pharmaceutical composition of claim 14, wherein said oil comprises a saturated fatty acid triglyceride, an unsaturated fatty acid triglyceride, a mixed saturated and unsaturated fatty acid triglyceride, a medium-chain fatty acid triglyceride, canola oil, coconut oil, palm oil, olive oil, soybean oil, sesame oil, corn oil, or mineral oil.

16. The pharmaceutical composition of claim 15, wherein said oil comprises a medium-chain fatty acid triglyceride.

17. The pharmaceutical composition of claim 14, wherein said pharmaceutical composition comprises a non-ionic surfactant.

18. The pharmaceutical composition of claim 17, wherein said non-ionic surfactant comprises a polyglycolized glyceride, an alkyl saccharide, an ester saccharide, or a polysorbate surfactant.

19. The pharmaceutical composition of claim 17, wherein said pharmaceutical composition comprises about 5 ± 2% (w/w) of said surfactant.

20. The pharmaceutical composition of claim 7, wherein said pharmaceutical composition comprises an emulsion.

21. The pharmaceutical composition of claim 7, wherein said drug particles comprise baclofen.

22. The pharmaceutical composition of claim 7, wherein said drug particles comprise levodopa or a levodopa prodrug and/or carbidopa or a carbidopa prodrug.

23. The pharmaceutical composition of claim 22, wherein said drug particles comprise carbidopa, and further comprising less than 8 µg of hydrazine per mg of carbidopa after 12 months storage at 5 ± 3 °C.

24. The pharmaceutical composition of claim 23, wherein said composition comprises less than 1 µg of hydrazine per mg of carbidopa after said 12 month storage.

25. The pharmaceutical composition of claim 22, wherein said drug particles comprise carbidopa, and further comprising less than 8 µg of hydrazine per mg of carbidopa after 12 months storage at 25 ± 3 °C.

26. The pharmaceutical composition of claim 25, wherein said composition comprises less than 1 µg of hydrazine per mg of carbidopa after said 12 month storage.

27. The pharmaceutical composition of claim 7, wherein said suspension comprises a paste.

28. The pharmaceutical composition of claim 7, wherein said suspension comprises benzoic acid or a benzoate salt.

29. The pharmaceutical composition of claim 2, wherein said suspension has a dynamic viscosity of at least 100 cP at 37 °C.

30. The pharmaceutical composition of claim 1, wherein said suspension has a dynamic viscosity of at least 1,000 cP at 37 °C.

31. The pharmaceutical composition of claim 1, wherein said suspension has a dynamic viscosity of at least 10,000 cP at 37 °C.

32. The pharmaceutical composition of claim 2, wherein said suspension has a dynamic viscosity of at least 10,000 cP at 37 °C.

33. The pharmaceutical composition of claim 3, wherein said suspension has a dynamic viscosity of at least 10,000 cP at 37 °C.

34. The pharmaceutical composition of claim 1, wherein said suspension has a dynamic viscosity of at least 100,000 cP at 37 °C.

35. The pharmaceutical composition of claim 7, wherein the D_{50} of the drug particles is less than or equal to 100 µm.

36. The pharmaceutical composition of claim 2, wherein the D_{50} of the solid drug particles is less than or equal to 100 µm.

37. The pharmaceutical composition of claim 3, wherein the D_{50} of the solid drug particles is less than or equal to 100 µm.

38. The pharmaceutical composition of claim 7, wherein the D_{50} of the drug particles is less than or equal to 25 µm.

39. The pharmaceutical composition of claim 17, wherein said non-ionic surfactant comprises a poloxamer.

40. The pharmaceutical composition of claim 2, wherein said pharmaceutical composition comprises a non-ionic surfactant.

41. The pharmaceutical composition of claim 3, wherein said pharmaceutical composition comprises a non-ionic surfactant.

42. The pharmaceutical composition of claim 2, wherein the shelf life of said pharmaceutical composition is 6 months or longer at 5 ± 3 °C and said pharmaceutical composition does not substantially cream or sediment when stored for 6 months at 5 ± 3 °C.

43. The pharmaceutical composition of claim 3, wherein the shelf life of said pharmaceutical composition is 6 months or longer at 5 ± 3 °C and said pharmaceutical composition does not substantially cream or sediment when stored for 6 months at 5 ± 3 °C.

44. The pharmaceutical composition of claim 2, wherein said suspension comprises less than or equal to about 12% (w/w) water.

45. The pharmaceutical composition of claim 3, wherein said suspension comprises less than or equal to about 12% (w/w) water.

46. The pharmaceutical composition of claim 2, comprising an edible oil.

47. The pharmaceutical composition of claim 3, comprising an edible oil.

48. The pharmaceutical composition of claim 2, wherein said pharmaceutical composition comprises an emulsion.

49. The pharmaceutical composition of claim 3, wherein said pharmaceutical composition comprises an emulsion.

50. The pharmaceutical composition of claim 2, wherein said suspension comprises a paste.

51. The pharmaceutical composition of claim 3, wherein said suspension comprises a paste.

52. The pharmaceutical composition of claim 3, wherein said drug particles comprise carbidopa, and further comprising less than 8 µg of hydrazine per mg of carbidopa after 12 months storage at 5 ± 3 °C.

53. The pharmaceutical composition of claim 52, wherein said composition comprises less than 1 µg of hydrazine per mg of carbidopa after said 12 month storage.